Cost - Effectiveness Data on Biologics Needed  

Oleh:

Sheridan, Cormac

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: Nature Biotechnology: The Science and Business of Biotechnology vol. 23 no. 3 (Mar. 2005), page 272-273.
Topik: COST EFFECTIVENESS; cost effectiveness; biologics needed

Ketersediaan

Perpustakaan Pusat (Semanggi) Nomor Panggil: NN9.2 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

A new report BioImpact, backed by european bioindustry lobbies, sets out the socioeconomic benefits of biotech based therapies in then disease areas but fails to include enough economic information to back its case. This reflects a widespread death of data that formally captures the cost effectiveness of biotech drugs. The information gap could become problematic as reimbursement agencies are increasingly reluctant to cover costly drughs without concrete evidence of their worth. Biotech companies, not only in europe, but also in the united states, have yet to start gathering data that would enable them to demonstrate the value of their products.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali